Dthera Sciences (fka DTHR)

[Werbe]

200,000 unrestricted shares, 100k @ DTC. Only product ever to receive breakthough device designation by FDA for the mitigation of Alzheimers sysmptoms of agitation and depression.

Share Structure as of 5-7-19

Authorized Shares - 66,666,667

Outstanding Shares - 2,669,602

Restricted - 2,461,694

Unrestricted - 207,908

Held at DTC - 107,406

Market Cap - 2,349,250

52WK RANGE 0.50 - 16.80

On February 22, 2019, Dthera Sciences, a Nevada corporation (the “Company”) entered into an exclusivity agreement (the “Agreement”) with a company headquartered in Japan (the “Partner”) with respect to the Company’s lead product, DTHR-ALZ, for the market of Japan only. The Agreement provides the Partner exclusive rights to perform market research and feasibility studies in Japan, along with rights to negotiate a licensing agreement or other transaction for the Japanese market during the agreed term, and the Company agreed to not pursue agreements or relationships with other entities in Japan during the exclusivity period. The agreement also requires that the Japanese partner keep the information and materials provided by the Company confidential. In the agreement, the Company agreed to sell certain of its tablets to the Partner for use in the feasibility studies and market research. The Partner paid a fee for the exclusivity rights for eight months, with the right to extend the exclusivity period by paying additional fees.

The Company’s product, DTHR-ALZ, is a medical device that has been granted Breakthrough Device designation by the U.S. Food and Drug Administration for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease. It features a customized computer tablet that digitally delivers an evidence-based behavioral intervention called Reminiscence Therapy to individuals with Alzheimer’s disease.

As of the date of this Current Report, the Company was actively exploring partnerships for the North American and European markets. The Company’s management believes that a strategic partner could support the delivery of DTHR-ALZ both economically and at scale, to large and underserved patient populations in these markets. Management further believes that such partnerships present an opportunity to challenge the increasing burden of neurodegenerative diseases on patients, caregivers, and healthcare providers in these major global markets.

DTHR- ALZ - Product Description

Dthera is developing DTHR-ALZ, a digital therapeutic that digitally delivers reminiscence therapy to Alzheimer’s sufferers in a scalable and personalized manner.

DTHR-ALZ has been granted Breakthrough Device designation by the FDA for the mitigation of the Alzheimer’s symptoms of agitation and depression. DTHR-ALZ is the first product to receive Breakthrough Device designation for the treatment of Alzheimer’s disease, and Dthera is only the second digital therapeutic company to receive this designation.

If granted FDA clearance, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer’s. The product was nominated by Rock Health as one of the top 4 Best Designed Products in Digital Health in 2018, alongside Apple Watch. Apple Health Records, and Sleep Tuner.

http://www.dthera.com/

https://www.otcmarkets.com/stock/DTHR/overview

https://www.linkedin.com/company/dthera-sciences/